These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
558 related articles for article (PubMed ID: 33741318)
1. Level up for culture models - How 3D cell culture models benefit SARS-CoV-2 research. Häfner SJ Biomed J; 2021 Mar; 44(1):1-6. PubMed ID: 33741318 [TBL] [Abstract][Full Text] [Related]
2. 3D culture models to study SARS-CoV-2 infectivity and antiviral candidates: From spheroids to bioprinting. de Melo BAG; Benincasa JC; Cruz EM; Maricato JT; Porcionatto MA Biomed J; 2021 Mar; 44(1):31-42. PubMed ID: 33602633 [TBL] [Abstract][Full Text] [Related]
3. Insights into antiviral mechanisms of remdesivir, lopinavir/ritonavir and chloroquine/hydroxychloroquine affecting the new SARS-CoV-2. Uzunova K; Filipova E; Pavlova V; Vekov T Biomed Pharmacother; 2020 Nov; 131():110668. PubMed ID: 32861965 [TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of current therapeutic options for COVID-19 - lessons to be learnt from SARS and MERS epidemic: A systematic review and meta-analysis. Zhong H; Wang Y; Zhang ZL; Liu YX; Le KJ; Cui M; Yu YT; Gu ZC; Gao Y; Lin HW Pharmacol Res; 2020 Jul; 157():104872. PubMed ID: 32360583 [TBL] [Abstract][Full Text] [Related]
5. A multinational, phase 2, randomised, adaptive protocol to evaluate immunogenicity and reactogenicity of different COVID-19 vaccines in adults ≥75 already vaccinated against SARS-CoV-2 (EU-COVAT-1-AGED): a trial conducted within the VACCELERATE network. Neuhann JM; Stemler J; Carcas A; Frías-Iniesta J; Bethe U; Heringer S; Tischmann L; Zarrouk M; Cüppers A; König F; Posch M; Cornely OA Trials; 2022 Oct; 23(1):865. PubMed ID: 36209129 [TBL] [Abstract][Full Text] [Related]
6. An overview of the safety, clinical application and antiviral research of the COVID-19 therapeutics. Wang D; Li Z; Liu Y J Infect Public Health; 2020 Oct; 13(10):1405-1414. PubMed ID: 32684351 [TBL] [Abstract][Full Text] [Related]
7. COVID-19 Vaccine: A comprehensive status report. Kaur SP; Gupta V Virus Res; 2020 Oct; 288():198114. PubMed ID: 32800805 [TBL] [Abstract][Full Text] [Related]
8. A Universal Design of Betacoronavirus Vaccines against COVID-19, MERS, and SARS. Dai L; Zheng T; Xu K; Han Y; Xu L; Huang E; An Y; Cheng Y; Li S; Liu M; Yang M; Li Y; Cheng H; Yuan Y; Zhang W; Ke C; Wong G; Qi J; Qin C; Yan J; Gao GF Cell; 2020 Aug; 182(3):722-733.e11. PubMed ID: 32645327 [TBL] [Abstract][Full Text] [Related]
9. COVID-19: Underpinning Research for Detection, Therapeutics, and Vaccines Development. Aljabali AAA; Bakshi HA; Satija S; Metha M; Prasher P; Ennab RM; Chellappan DK; Gupta G; Negi P; Goyal R; Sharma A; Mishra V; Dureja H; Dua K; Tambuwala MM Pharm Nanotechnol; 2020; 8(4):323-353. PubMed ID: 32811406 [TBL] [Abstract][Full Text] [Related]
10. Potential Therapeutic Targets and Vaccine Development for SARS-CoV-2/COVID-19 Pandemic Management: A Review on the Recent Update. Anand U; Jakhmola S; Indari O; Jha HC; Chen ZS; Tripathi V; Pérez de la Lastra JM Front Immunol; 2021; 12():658519. PubMed ID: 34276652 [TBL] [Abstract][Full Text] [Related]
11. Safety and Efficacy of Different Therapeutic Interventions on Prevention and Treatment of COVID-19. Gyanwali P; Sharma S; Pant S; Koirala P; Adhikari K; Koirala J; Dhimal M J Nepal Health Res Counc; 2020 Sep; 18(2):151-158. PubMed ID: 32969369 [TBL] [Abstract][Full Text] [Related]
12. The characteristics of BCR-CDR3 repertoire in COVID-19 patients and SARS-CoV-2 vaccinated volunteers. Xiao J; Luo Y; Li Y; Yao X J Med Virol; 2024 Mar; 96(3):e29488. PubMed ID: 38415507 [TBL] [Abstract][Full Text] [Related]
13. An evidence-based systematic review on emerging therapeutic and preventive strategies to treat novel coronavirus (SARS-CoV-2) during an outbreak scenario. Gudadappanavar AM; Benni J J Basic Clin Physiol Pharmacol; 2020 Sep; 31(6):. PubMed ID: 32924964 [TBL] [Abstract][Full Text] [Related]
14. Vaccines against SARS-CoV-2 variants and future pandemics. Park T; Hwang H; Moon S; Kang SG; Song S; Kim YH; Kim H; Ko EJ; Yoon SD; Kang SM; Hwang HS Expert Rev Vaccines; 2022 Oct; 21(10):1363-1376. PubMed ID: 35924678 [TBL] [Abstract][Full Text] [Related]
15. Safety and immunogenicity of a protein subunit COVID-19 vaccine (ZF2001) in healthy children and adolescents aged 3-17 years in China: a randomised, double-blind, placebo-controlled, phase 1 trial and an open-label, non-randomised, non-inferiority, phase 2 trial. Gao L; Li Y; He P; Chen Z; Yang H; Li F; Zhang S; Wang D; Wang G; Yang S; Gong L; Ding F; Ling M; Wang X; Ci L; Dai L; Gao GF; Huang T; Hu Z; Ying Z; Sun J; Zuo X Lancet Child Adolesc Health; 2023 Apr; 7(4):269-279. PubMed ID: 36803632 [TBL] [Abstract][Full Text] [Related]
16. SARS-CoV-2 variants and COVID-19 vaccines: Current challenges and future strategies. Gong W; Parkkila S; Wu X; Aspatwar A Int Rev Immunol; 2023; 42(6):393-414. PubMed ID: 35635216 [TBL] [Abstract][Full Text] [Related]
18. Vaccine Candidates against Coronavirus Infections. Where Does COVID-19 Stand? Al-Kassmy J; Pedersen J; Kobinger G Viruses; 2020 Aug; 12(8):. PubMed ID: 32784685 [TBL] [Abstract][Full Text] [Related]
19. Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial. Chen GL; Li XF; Dai XH; Li N; Cheng ML; Huang Z; Shen J; Ge YH; Shen ZW; Deng YQ; Yang SY; Zhao H; Zhang NN; Zhang YF; Wei L; Wu KQ; Zhu MF; Peng CG; Jiang Q; Cao SC; Li YH; Zhao DH; Wu XH; Ni L; Shen HH; Dong C; Ying B; Sheng GP; Qin CF; Gao HN; Li LJ Lancet Microbe; 2022 Mar; 3(3):e193-e202. PubMed ID: 35098177 [TBL] [Abstract][Full Text] [Related]
20. COVID-19: morphology and mechanism of the SARS-CoV-2, global outbreak, medication, vaccines and future of the virus. Bhattacharyya P; Das S; Aich S; Sarkar J Front Biosci (Elite Ed); 2021 Dec; 13(2):272-290. PubMed ID: 34937314 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]